This phase I study evaluates the safety and efficacy of OH2 as single agent or in combination
with Keytruda, an anti-PD-1 antibody, in patients with malignant solid tumors (Melanoma).
OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus
type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the
delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF)
may induce a more potent antitumor immune response.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.